Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Status unconfirmed · Phase 2

Conditions studied: Lung Cancer

In brief

RATIONALE: Lometrexol may stop or slow the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Folic acid may be effective in preventing or lessening the side effects of lometrexol. Combining lometrexol with folic acid may be an effective treatment for non-small cell lung cancer. PURPOSE: Phase II trial to study the effectiveness of combining lometrexol with folic acid in treating patients who have stage IIIB or stage IV non-small cell lung cancer that has been previously treated.

Key facts

Study ID

NCT00033722

Run by

Tularik

Starts

2002-02-01

Last updated by the study team

2014-01-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• UCSF Cancer Center and Cancer Research Institute — San Francisco, California, United States
• Cancer Centers of Florida (U.S. Oncology) — Orlando, Florida, United States
• Louisiana State University School of Medicine — New Orleans, Louisiana, United States
• US Oncology - Albany Regional Cancer Center — Albany, New York, United States
• U.S. Oncology Research Inc. — Houston, Texas, United States
• Tyler Cancer Center — Tyler, Texas, United States
• Cancer Care Northwest — Spokane, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.